⌕
Kazia Therapeutics · KZIA · Nasdaq
Tenet 50 · Mixed
Compare
$5.37−2.19%At closeTenet 50 · Mixed
$5.37−0.12 (−2.19%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Kazia Therapeutics (KZIA) Earnings Forecast

Analysts expect Kazia Therapeutics (KZIA) to lose $1.08 a share in FY27, the average of 2 estimates as of Nov 20, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
FY27 consensus EPS
$−1.08
2 analysts
FY28 consensus EPS
$−1.49
2 analysts · low $−2.40, high $−0.59
EPS revisions, 30 days
+39.1%
$−1.48 to $−0.90
Disagreement, FY27
$0.00
wide, $−1.08 to $−1.08

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 20, 2026 · we check it nightly

Analysts expect Kazia Therapeutics to earn $0.94 a share in FY31; 1 analyst publishes an estimate for FY31.

Forward P/E · FY27E
n/m
a multiple of a loss is not meaningful
Coverage · FY27
2 · 4
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY27 EPS consensus is $−0.90, a loss that narrowed 37.1% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−16.6%+14.3%+45.3%FY27 +37.1%FY28 +25.2%Aug 22Nov 20
EPS30 days90 daysshown aboveSince Jul 10
FY272 analysts▲ +39.1%$−1.48 to $−0.90▲ +37.1%$−1.43 to $−0.90▲ +36.3%$−1.42 to $−0.90
FY282 analysts▲ +31.0%$−2.04 to $−1.41▲ +25.2%$−1.88 to $−1.41▲ +19.7%$−1.75 to $−1.41
Dec '261 analyst1 of 30 days0.0% so far1 of 90 days0.0% so far◆ 0.0%$−0.07 to $−0.07
Jun '271 analyst▲ +84.6%$−0.50 to $−0.0837 of 90 days+84.6% so far▲ +84.6%$−0.50 to $−0.08

Contributors at both ends of the window: FY27 1 and 2. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price at last close · consensus as of Nov 20, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from FY31 on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY31
$0.0B
1 analyst · low $0.0B, high $0.0B · thin coverage
Multiple · EV/EBITDA · yours
No year of positive EBITDA or earnings on record to take a default from, so the multiple can only be yours.
Receipt · KZIA · FY31Nov 20, 2026
Implied, a share
Waiting

We hold no net cash and no diluted share count for this company, so an EBITDA multiple cannot be bridged to a price a share here. The sum stops rather than guessing the bridge.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY27, so there is neither a multiple of those earnings to pay nor a rate to grow from.

How much do analysts disagree?

For FY31, estimates run from $0.94 to $0.94 around an average of $0.94, drawn by 1 analyst.

FY27E2 analysts
$−1.08 · only 2 estimates
FY28E2 analysts
$−2.40 to $−0.59 · $1.81 wide
FY29E1 analyst
$−1.65 · only 1 estimate
FY30E1 analyst
$−2.13 · only 1 estimate
FY31E1 analyst
$0.94 · only 1 estimate

The dashed line is FY26 filed $−0.01, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Kazia Therapeutics to lose $0.22 a share in the December quarter, the one estimate published. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$1,507.7K
1 analyst, 1,507.7 to 1,507.7 in $K

For the June quarter, analysts expect a loss of $0.23 a share.

Does Kazia Therapeutics usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Kazia Therapeutics begins on Jul 10, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 10, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
scores begin at the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Kazia Therapeutics on Jul 10, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow −9.8% in FY28. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

2 analysts publish an EPS estimate for FY27 and 4 publish revenue. Coverage thins with distance: 1 EPS estimate for FY31. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
42
FY27E
62
FY28E
31
FY29E
31
FY30E
41
FY31E
The FY27 panel held 1 analyst when our record of it began on Jul 10, 2026 and holds 2 tonight.

The full consensus, year by year

Consensus as of Nov 20, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
−0.00.00.1historyStreet forecastFY23FY26FY31E

Coverage thins with distance: 4 revenue estimates for FY27, 4 for FY31.

Diluted EPS · $filed · consensus average · band = low to high
−2.60−0.761.07historyStreet forecastFY23FY26FY31E

Out-year bands widen as fewer analysts publish: 2 EPS estimates for FY27, 1 for FY31.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY26Filed0.0—−0.01————as filed—
FY27E0.00.0 to 0.0▲112.5%a−1.08−1.08 to −1.08n/ca−0.0−0.00.014 · 2n/m
FY28E0.00.0 to 0.0▼9.8%−1.49−2.40 to −0.59—−0.0−0.00.016 · 2n/m
FY29E0.00.0 to 0.0n/cb−1.65−1.65 to −1.65n/cb−0.0−0.00.013 · 1n/m
FY30E0.00.0 to 0.0▲1148.7%−2.13−2.13 to −2.13—−0.0−0.00.013 · 1n/m
FY31E0.10.1 to 0.1▲262.6%0.940.94 to 0.94—0.00.00.014 · 15.7×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 2 EPS estimates for FY27, 4 for revenue. Not investment advice.

What do analysts expect Kazia Therapeutics to earn in FY27?

Analysts expect Kazia Therapeutics to lose $1.08 a share in FY27, the average of 2 estimates as of Nov 20, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.